Strategies for prescribing statins

BMJ

Volumn 336, Issue 7639, 2008, Pages 288-289

  Donner Banzhoff, Norbert ^a   Sönnichsen, Andreas ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN; STATIN;

ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SCREENING; EDITORIAL; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTIONS, DRUG;

EID: 39449132810     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39387.573947.80     Document Type: Editorial

References (14)

1. Shepherd J. Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs. Lancet 2002;359:2271-3.
2. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. Clinical guideline 97. 2007. www.sign-ac.uk/pdf/sign97.pdf
3. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
4. National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). 2002.www.nhlbi.nih.gov/ guidelines/cholesterol/atp3full.pdf.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
6. Schering-Plough News Release. Merck/Schering-Plough Pharmaceuticals provides results of the ENHANCE trial. www.sch-plough.com/schering_plough/ news/release. jsp?releaseID=1095943.
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
8. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
9. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994;344:1383-9.
12. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
13. Ravnskov U, Rosch PJ, Sutter MC, Houston MC. Should we lower cholesterol as much as possible? BMJ 2006;332:1330-2.
14. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005;365:434-41.